---
title: Modafinil for the Treatment of Cocaine Dependence - 1
nct_id: NCT00100100
overall_status: COMPLETED
phase: PHASE2
sponsor: National Institute on Drug Abuse (NIDA)
study_type: INTERVENTIONAL
primary_condition: Cocaine-Related Disorders
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00100100.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00100100"
ct_last_update_post_date: 2017-01-12
last_seen_at: "2026-05-12T07:19:51.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Modafinil for the Treatment of Cocaine Dependence - 1

**Official Title:** Modafinil for the Treatment of Cocaine Dependence

**NCT ID:** [NCT00100100](https://clinicaltrials.gov/study/NCT00100100)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 210
- **Lead Sponsor:** National Institute on Drug Abuse (NIDA)
- **Conditions:** Cocaine-Related Disorders
- **Start Date:** 2004-10
- **Completion Date:** 2006-12
- **CT.gov Last Update:** 2017-01-12

## Brief Summary

The purpose of this study is to evaluate the efficacy and safety of modafinil in reducing cocaine use in subjects with cocaine dependence.

## Detailed Description

This is a double-blind, placebo-controlled, parallel group design study to evaluate the efficacy and safety of modafinil in reducing cocaine use in subjects with cocaine dependence.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 99 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Participant must have DSM-IV diagnosis of cocaine dependence as determined by SCID.
* Must be seeking treatment for cocaine dependence.
* Must be able to understand and provide written informed consent.

Exclusion Criteria:

* Please contact the study site for more information.
```

## Interventions

- **Modafinil** (DRUG)

## Primary Outcomes

- **Cocaine abstinence**

## Locations (6)

- Boston University Medical Center, Boston, Massachusetts, United States
- New York VA Medical Center, New York, New York, United States
- Cincinnati Addiction Research Center, Cincinnati, Ohio, United States
- Western Psychiatric Institute & Clinic, Pittsburgh, Pennsylvania, United States
- RHD Professional Plaza 4, Dallas, Texas, United States
- UTHSCSA, San Antonio, Texas, United States

## Recent Field Changes (last 30 days)

- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.boston university medical center|boston|massachusetts|united states` — added _(2026-05-12)_
- `locations.new york va medical center|new york|new york|united states` — added _(2026-05-12)_
- `locations.cincinnati addiction research center|cincinnati|ohio|united states` — added _(2026-05-12)_
- `locations.western psychiatric institute & clinic|pittsburgh|pennsylvania|united states` — added _(2026-05-12)_
- `locations.rhd professional plaza 4|dallas|texas|united states` — added _(2026-05-12)_
- `locations.uthscsa|san antonio|texas|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00100100.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00100100*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*